Compare interventions

Use the same six evidence dimensions for both. This prevents a strong animal result for one product being compared with a human clinical result for another.

First intervention

versus

Second intervention

Cardiometabolic

Omega-3 fatty acids

Useful human evidence

Some cardiovascular effects are real, but formulation, dose and baseline risk matter greatly.

Human clinical outcomes Moderate

Human biomarkers Strong

Animal lifespan Preliminary

Mechanistic plausibility Strong

Safety certainty Moderate

Direct longevity relevance Limited

Verdict: Omega-3 is not one intervention. Dietary fish, mixed EPA/DHA supplements and high-dose prescription EPA have different evidence. Some analyses find modest reductions in selected cardiovascular events, while high-dose regimens may increase atrial fibrillation risk in susceptible populations. No reliable evidence supports generic fish-oil capsules as a universal life-extension treatment.

Open full dossier

NAD+ precursor

NMN

Early human evidence

Raises NAD-related biomarkers; broad healthspan benefits have not followed reliably.

Human clinical outcomes Preliminary

Human biomarkers Moderate

Animal lifespan Limited

Mechanistic plausibility Moderate

Safety certainty Limited

Direct longevity relevance Preliminary

Verdict: Nicotinamide mononucleotide can raise NAD-related measures in humans, which confirms biological activity. Trials have reported selected metabolic or functional effects, but results are mixed, studies are generally short, and no human evidence shows slower ageing or longer life.

Open full dossier